[CEA, TPA and APP as a guide in the surgical therapy and follow-up of pancreatic cancer].
Lucev
M
M
Bottani
G
G
Colombo
P L
PL
Tinozzi
S
S
D000209:Acute-Phase Proteins; D000230:Adenocarcinoma / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery; D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000032:analysis*; D001798:Blood Proteins / Q000032:analysis*; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery; D010455:Peptides / Q000097:blood*; D011300:Preoperative Care; D019396:Tissue Polypeptide Antigen
D000209:Acute-Phase Proteins; D000951:Antigens, Neoplasm; D001798:Blood Proteins; D002272:Carcinoembryonic Antigen; D010455:Peptides; D019396:Tissue Polypeptide Antigen
CEA, TPA, APP come guida nella terapia chirurgica e nel follow-up del carcinoma pancreatico.